Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of QX002N injection in patients with active ankylosing spondylitis
CTR20222799Phase 2Completed
- Sponsor
- Qiansin
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crusekitug in ankylosing spondylitis (AS), sponsored by Qiansin. Primary endpoint: Long-term safety of QX002N over 104 weeks. Started Jan 2023; status: completed.
02
Drugs
crusekitug
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20222799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222799.